Navigation Links
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Date:11/7/2013

onday, December 9, 5:00 pm CT, 393-394
  • Oral presentation: Myeloma: Therapy, excluding Transplantation II
  • Abstract # 687
  • Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Lenalidomide Extended Dosing (CRD-R) Induces High Rates of MRD Negativity in Newly Diagnosed Multiple Myeloma (MM) Patients

    • Dr. Neha Korde, Multiple Myeloma Section, National Cancer Institute, National Institutes of Health
    • Monday, December 9, 3:30 pm CT, 393-394
    • Oral presentation: Myeloma: Therapy, excluding Transplantation: Treatment Options for Newly Diagnosed Multiple Myeloma Patients
    • Abstract # 538

    Serum Heavy-Light Chains (HLC) and Free Light Chains (FLC) As Predictors For Early CR In Newly Diagnosed Myeloma Patients Treated With Carfilzomib, Lenalidomide, and Dexamethasone (CRd)

    • Dr. Manisha Bhutani, Multiple Myeloma Section, National Cancer Institute, National Institutes of Health
    • Monday, December 9, 7:30 pm CT, 393-394
    • Oral presentation: Myeloma: Therapy, excluding Transplantation: Advances in Multiple Myeloma and Plasma Cell Leukemia
    • Abstract # 762

    Phase I/II Dose Expansion of a Multi-Center Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma

    • Dr. Jatin Shah, The University of Texas MD Anderson Cancer Center
    • Monday, December 9, 5:45 pm CT, 393-394
    • Oral presentation: Myeloma: Therapy, excluding Transplantation II
    • Abstract # 690

    Carfilzomib, Rituximab and Dexamethasone (CaRD) is highly active and offers a neuropathy sparing approach for proteasome-inhibitor based the
    '/>"/>

    SOURCE Onyx Pharmaceuticals, Inc.; Amgen
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
    2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
    3. Amgen Announces 2012 First Quarter Dividend
    4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
    5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
    6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
    7. Amgen to Acquire Micromet
    8. Amgen to Present at the Leerink Swann Global Healthcare Conference
    9. Amgen Announces 2012 Third Quarter Dividend
    10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
    11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/1/2014)... September 01, 2014 The global ... million by 2019 from $1,070.7 million in 2014, ... to 2019. The global oligonucleotide synthesis market is ... applications, end users, and geography. The synthesized oligonucleotides ... rate in the oligonucleotide synthesis market during the ...
    (Date:8/31/2014)... 2014 Market Research Report ... and in-depth research report on the Polyacrylamide ... including Polyacrylamide definition, classification, application, and industry ... This research covers the international market analysis, ... industry analysis covering macroeconomic environment & economic ...
    (Date:8/29/2014)... electrons, but one of the most promising technologies for ... on light (photons) instead of electrons. First, it is ... single photons and control their direction. Researchers around the ... this control, but now scientists at the Niels Bohr ... photons emitted one at a time and in a ...
    (Date:8/29/2014)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the six months ended June 30, 2014. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... , Announced top-line results related to the eight ... enrolled in the Phase 2 iDEAL Study evaluating ...
    Breaking Biology Technology:9.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 49.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 5International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Breakthrough in light sources for new quantum technology 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4
    ... /PRNewswire/ -- The Nano Science and Technology Institute ... will take place May 3-7, 2009 at the George R. ... 12th year, the largest and most prominent Nanotechnology event is ... Micro and Bio technology executives, who will gather to promote ...
    ... CLINTON, N.J., Jan. 8 Ikaria Holdings, Inc. today ... present at the 27th Annual JPMorgan Healthcare Conference on ... The conference will be held January 12-15 at The ... Holdings, Inc. , Ikaria Holdings, Inc. is a ...
    ... /PRNewswire/ - Aegera Therapeutics Inc. announced today the ... Phase 2 study of AEG35156, their targeted antisense ... , The study, entitled "A Phase 2, Multicenter, ... Apoptosis (XIAP) Antisense AEG35156 Given In Combination With ...
    Cached Biology Technology:NSTI Announces the 12th Annual Nanotech Conference & Expo 2009 May 3-7, at the George R. Brown Convention Center in Houston, Texas 2NSTI Announces the 12th Annual Nanotech Conference & Expo 2009 May 3-7, at the George R. Brown Convention Center in Houston, Texas 3NSTI Announces the 12th Annual Nanotech Conference & Expo 2009 May 3-7, at the George R. Brown Convention Center in Houston, Texas 4Ikaria(R) to Present at 27th Annual JPMorgan Healthcare Conference 2Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer 2
    (Date:9/1/2014)... after birth, every child in the U.S. undergoes a ... conditions, including sickle cell disease. Thousands of children born ... many suffer and die from the disease each year. ... to at least some of those deaths. , ... in the lab of George Whitesides, the Woodford L. ...
    (Date:9/1/2014)... basic building block of DNAcould initiate fragile X syndrome, the most ... The Journal of Cell Biology . , ... on the X chromosome called fragile X mental retardation 1 ... men carry a so-called premutation, in which a series of DNA ... slightly longer than normal. These repeats are prone to even further ...
    (Date:9/1/2014)... to a life without light. They emit echolocation sounds and ... to obstacles or prey. In their brains, they have a ... by researchers at Technische Universitt Mnchen (TUM) has shown for ... factors. , Closer objects appear larger ... object, the number of activated neurons in its brain increases. ...
    Breaking Biology News(10 mins):Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3A nucleotide change could initiate fragile X syndrome 2Zooming in for a safe flight 2
    ... June 1, 2010 -- The National Oceanic and Atmospheric ... of Miami (UM) to continue to lead its partnership ... (CIMAS). NOAA and UM scientists have worked ... of climate, hurricanes, and marine ecosystems along the southeastern ...
    ... Since the 1990s, a green fluorescent protein known simply as ... Northwest jellyfish, GFP allows scientists to visualize proteins inside of ... Two years ago, biologists who discovered and developed the protein ... work. However, using GFP as a fluorescent probe has ...
    ... viable due to aberrant chromosome distribution if they had ... German Cancer Research Center have investigated which genes are ... revealed that cancer cells rely on the tension ... Thus, proteins which maintain this tension are promising targets ...
    Cached Biology News:NOAA selects University of Miami to lead major southeastern US cooperative institute 2NOAA selects University of Miami to lead major southeastern US cooperative institute 3MIT chemists design new way to fluorescently label proteins 2No relaxing for cancer cells 2
    The Programmable MP-5000P-F Power Supply can be applied for any Microfluidic application....
    ...
    Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
    ... Major Science Smart Minis 150V power supply ... mini power supplies designed to meet most ... to use unit. The Minis 150V power ... The Minis Power Supply is designed for ...
    Biology Products: